Neuro-oncology

Providing a clear picture to support patient care

Central nervous system, or CNS, tumors are a diverse, heterogeneous group of nearly 100 unique tumor types.¹ They are the tenth leading cause of cancer-associated death in adults and the leading cause of cancer-associated deaths in pediatric patients.²

Understanding specific molecular markers present in CNS tumors not only facilitates an accurate diagnosis that meets classification guidelines, but it can also guide treatment decisions and therapeutic timelines. Attaining broad molecular and cytogenic information is also needed to select the most appropriate treatment options, whether standard, off-label, or clinical trial.

Our comprehensive approach to neuro-oncology testing is rooted in our mission to provide the right diagnosis at the right time to enable informed clinical decisions and ultimately improve outcomes for patients with CNS tumors. By performing immunohistochemical, molecular, and cytogenetic analysis on all patients, our testing approach provides a more complete assessment and enables a clearer picture of diagnosis, prognosis, and treatment options.